Seeking Alpha

PDL BioPharma (PDLI): Q2 EPS of $0.52 beats by $0.08. Revenue of $12.9M (+3.1% Y/Y) in-line....

PDL BioPharma (PDLI): Q2 EPS of $0.52 beats by $0.08. Revenue of $12.9M (+3.1% Y/Y) in-line. Shares +1.1% AH. (PR)
Comments (1)
  • korneel
    , contributor
    Comments (9) | Send Message
    "On June 8, 2012, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab). Perjeta is approved
    in combination with Herceptin ® and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have
    not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
    Genentech notified PDL on June 18, 2012, that Perjeta is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter
    following the first quarter of Perjeta sales in accordance with Genentech’s license agreements with PDL."


    is this product part of the queen et al patent or is this one seperated from that group?
    2 Aug 2012, 11:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: